Add a description, image, and links to the molecule-driver topic page so that developers can more easily learn about it.

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.

The new research, however, paints a different picture. The team discovered a gene that produces an RNA molecule—not a protein—controls where dark pigments are made during butterfly metamorphosis.

(Alliance News) - GSK PLC on Wednesday announced progress in Japan on treating chronic hepatitis B and chronic rhinosinusitis with nasal polyps, while it welcomed a decision by the Delaware ...

MRNA-1403 is under clinical development by Moderna and currently in Phase II for Norovirus Infections. According to GlobalData, Phase II drugs for Norovirus Infections does not have sufficient ...

PF-07799544 is under clinical development by Pfizer and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) ...

The company's oncology portfolio, consisting of Zejula, Blenrep, Jemperli, and Ojjaara/Omjjara, reported total sales of $450 million in the second quarter of 2024, up 136.8% year-on-year and 30.1% ...

Wall Street futures were slightly higher ahead of the bell on Monday as market participants cheered news that the Federal Reserve appeared to be on the cusp of making interest rate cuts. As of ...

A certified sleep science coach and mattress expert, JD has been reviewing online mattresses professionally for the past five years. During that time, he's tested well over 150 beds and dedicated ...

Recent data showed a benefit when using a BLENREP (belantamab mafodotin) in relapsed or refractory multiple myeloma across all pre-specified subgroups of patients, including those with unfavorable ...